

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICATION NO. 10/523047

APPLICANT
Lane, Roger Michael et al.
FILING DATE
August 06, 2003Group
1634

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AM	2000/19985	04/13/00	WO			<input type="checkbox"/>	<input type="checkbox"/>
AN	1999/25363	05/27/99	WO			<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	FORETTE F. et al., "A phase II study in patients with alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®), European Journal of Neurology, vol. 6, (4), pp. 243-429, (1999)
AS	FARLOW, M.R. et al., "Differential qualitative responses to rivastigmine in APOE ε4 carriers and noncarriers", The Pharmacogenomics Journal, vol. 4, pp. 332-335 (2004)
AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.